EODData

MEMBERSHIP REGISTER LOG IN

ASX, TLX: Telix Pharmaceuticals Limited

20 Nov 2025
LAST:

13.88

CHANGE:
 0.06		OPEN:
13.95		HIGH:
14.20		ASK:
29.38		VOLUME:
1.28M
CHG(%):
0.43		PREV:
13.94		LOW:
13.82		BID:
29.22		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
20 Nov 2513.9514.2013.8213.881.28M
19 Nov 2514.0014.0913.7513.941.58M
18 Nov 2513.9214.3113.8814.061.29M
17 Nov 2514.1014.2013.7614.201.61M
14 Nov 2514.5014.7814.0114.132.14M
13 Nov 2514.9415.1714.8514.981.03M
12 Nov 2515.7015.8514.8514.932.97M
11 Nov 2515.4215.8115.3615.621.21M
10 Nov 2515.0215.3214.8315.321.39M
07 Nov 2515.2015.3914.9815.01968.3K

PROFILE

Name:Telix Pharmaceuticals Limited
About:Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:55 Flemington Road, North Melbourne, VIC, Australia, 3051
Website:https://telixpharma.com
ISIN:AU000000TLX2
FIGI:BBG00HZHXWM5

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:395.25 
Forward P/E:56.46 
PEG Ratio:56.46 
Price to Sales:8.10 
Price to Book:12.68 
Profit Margin:0.02 
Operating Margin:0.00 
Return on Assets:0.02 
Return on Equity:0.03 
EPS Ratio:0.03 
Revenue:1.014B 
EBITDA:57.4M 
Shares:334.72M 
Market Cap:4.646B 

TECHNICAL INDICATORS

MA5:14.041.2%
MA10:14.615.2%
MA20:15.3210.4%
MA50:15.3110.3%
MA100:17.2924.6%
MA200:21.9958.4%
RSI14:19.95 
WPR14:-100.00 
MTM14:-1.93
ROC14:-0.12 
ATR:0.53 
Week High:15.179.3%
Week Low:13.750.9%
Month High:17.2524.3%
Month Low:13.7558.4%
Year High:31.97130.3%
Year Low:13.304.4%
Volatility:45.48